Peptides TA-1, MOTS-c and Retatrutide in Integrative Cancer Care
Omics LongvevityPublished on: 13/09/2026
Discover the latest research on TA-1 (Thymosin Alpha-1), MOTS-c and Retatrutide as emerging adjunctive therapies in cancer. Learn about PD-1 pathways, USP7, LARS1, immune metabolism, AMPK signalling, tumour microenvironment modulation and the current
anti-ageingpeptidesRetatrutideIntegrative Cancer Care
